Inato, a Paris, France-based technology platform enabling access to inclusive clinical trials, closed $20m Series A2 funding.
Backers included return and lead investor Cathay Innovation, return investor Obvious Ventures, as well as new investors La Maison and Top Harvest Capital.
The company intends to use the new funding for continued product innovation, international growth, and hiring of talent. Inato will advance its diversity product offering to enable sponsors to strategically meet their diversity goals based on new FDA requirements, invest in oncology-specific innovation, further define and scale its data model to continue to improve matching reliability between community sites and sponsor trials.
Led by Co-Founder and CEO Kourosh Davarpanah, Inato Inato makes clinical trials accessible, inclusive, and efficient for patients, community-based clinical researchers, and pharmaceutical companies across the globe. By enabling community research sites to effectively select the right opportunities for them, Inato is helping bring the right trials to patients — regardless of who they are or where they live. To do this, the platform connects global pharmaceutical companies with a broader range of community research sites, while ensuring high performance through collaborative, evidence-based enrollment planning and ongoing support.
Launched in late 2020, the platform has amassed over 2,500 community research sites that support more than 70 disease areas in more than 60 countries. Inato has formed partnerships with a third of the top 30 pharmaceutical companies.
FinSMEs
29/03/2023